Incidence of and risk factors for upper gastrointestinal complications in patients taking low-dose aspirin in Japan

Hepato-Gastroenterology

Volumn 58, Issue 105, 2011, Pages 229-234

  Fujisawa, Nobutaka ^a   Inamori, Masahiko ^b   Endo, Hiroki ^b   Uchiyama, Takashi ^b   Hosono, Kunihiro ^b   Akiyama, Tomoyuki ^b   Tomimoto, Ayako ^a   Koyama, Sigeru ^a   Sawabe, Aya ^c   Tanida, Emiko ^c   Yanagisawa, Shogo ^d   Hata, Yasuo ^d   Okada, Kazuhisa ^e   Atsukawa, Kazuhiro ^e   Watanabe, Seitaro ^f   Kawamura, Harunobu ^g   Higurashi, Takuma ^h   Nagase, Hajime ^h   Akimoto, Keiko ⁱ   Matsuhashi, Nobuyuki ⁱ   Nakajima, Atsushi ^b   more..

^a TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^c Machida Municipal Hospital   (Japan)

^d CHIGASAKI MUNICIPAL HOSPITAL   (Japan)

^e Hiratsuka City Hospital   (Japan)

^f Japan Organization of Occupational Health and Safe   (Japan)

^g Odawara Municipal Hospital   (Japan)

^h YOKOHAMA ROSAI HOSPITAL   (Japan)

ⁱ Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

Author keywords

Gastrointestinal bleeding; Histamine type2 receptor antagonist; Low dose aspirin; Peptic ulcer; Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STEROID; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENTERIC COATED TABLET; FEMALE; GASTRODUODENAL EROSION; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; JAPAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RISK FACTOR; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHI-SQUARE DISTRIBUTION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HISTAMINE AGONISTS; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PEPTIC ULCER; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; UPPER GASTROINTESTINAL TRACT;

EID: 79955009106     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:159-168.
2. Awtry EH, Loscalzo J: Aspirin. Circulation 2000; 101:1206-1218. (Pubitemid 30146625)
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
4. Hayden M, Pignone M, Phillips C, Mulrow C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 136:161-172.
5. de Gaetano G; Collaborative Group of the Primary Prevention Project: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357:89-95.
6. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352:1293-1304.
7. Laine L: Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? Aliment Pharmacol Ther. 2006; 24:897-908.
8. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996; 348:1413-1416. (Pubitemid 26395236)
9. Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J, Sanz M, Montoro M, Sáinz R: Nitro-vasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000; 343:834-839.
10. Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, Tsukui T, Osawa H, Sakurai Y, Yoshino J, Mizokami Y, Mine T, Arakawa T, Kuwayama H, Saigenji K, Yakabi K, Chiba T, Shimosegawa T, Sheehan JE, Perez-Gutthann S, Yamaguchi T, Kaufman DW, Sato T, Kubota K, Terano A: Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006; 62:765-772.
11. Dammann HG, Burkhardt F, Wolf N: Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther. 1999; 13:1109-1114. (Pubitemid 29374114)
12. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ: Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991; 32:77-83.
13. Cole AT, Hudson N, Liew LC, Murray FE, Hawkey CJ, Heptinstall S: Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment Pharmacol Ther. 1999; 13:187-193.
14. Petroski D: A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies. Am J Gastroenterol. 1986; 81:26-28.
15. Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterol. 2001; 120:594-606.
16. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075-1078.
17. García Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individ- ual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:769-772. (Pubitemid 24098698)
18. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. N Engl J Med. 1996; 334:1435-1439.
19. Raskin JB: Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med. 1999; 106:3S-12S.
20. Sugano K: Japanese guideline for the management of gastric ulcer. Nippon Rinsho 2004; 62:1389-95.
21. Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M, Aleman S, Nicolas D, Feu F, González-Pérez A, Borda A, Castro M, Poveda MJ, Arenas J; Investigators of the Asociación Española de Gastroenterologí a (AEG): Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007; 102:507-515. (Pubitemid 46328156)
22. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005; 22:795-801.
23. Laine L, Maller ES, Yu C, Quan H, Simon T: Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterol. 2004; 127:395-402. (Pubitemid 39091887)